MyFinsight
Home
Blog
About
Maturities of short-term
investments
$11,528K
(-67.08%↓ Y/Y)
Sales of short-term
investments
$2,088K
(68.93%↑ Y/Y)
Proceeds from sale of
common stock
$212K
Proceeds from exercise of
options
$1K
(-66.67%↓ Y/Y)
Net cash provided by
(used in) investing...
$12,269K
(162.70%↑ Y/Y)
Net cash provided by
financing activities
$149K
(4866.67%↑ Y/Y)
Canceled cashflow
$1,347K
Canceled cashflow
$64K
Net change in cash
and cash...
$653K
(101.60%↑ Y/Y)
Canceled cashflow
$11,765K
Purchases of short-term
investments
$1,303K
(-97.66%↓ Y/Y)
Capital expenditures
$44K
(69.23%↑ Y/Y)
Stock-based compensation
expense
$920K
(-69.82%↓ Y/Y)
Prepaid expenses and
other current assets
-$136K
(64.95%↑ Y/Y)
Amortization of right-of-use
assets
$135K
(-50.00%↓ Y/Y)
Depreciation
$87K
(-53.48%↓ Y/Y)
Accounts receivable and
unbilled receivable
-$2K
(99.19%↑ Y/Y)
Payment of issuance
costs
$64K
Net cash used in
operating activities
-$11,765K
(44.30%↑ Y/Y)
Canceled cashflow
$1,280K
Net loss
-$9,232K
(66.28%↑ Y/Y)
Accounts payable and
accrued liabilities
-$3,477K
(-207.88%↓ Y/Y)
Operating lease
liabilities
-$189K
(44.08%↑ Y/Y)
Other assets
$83K
(-75.00%↓ Y/Y)
Accretion of discounts on
short-term investments,...
$64K
(-85.39%↓ Y/Y)
Back
Back
Cash Flow
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)
source: myfinsight.com